Tag Archives: Nucala®

Tony Wood to succeed Dr Hal Barron as Chief Scientific Officer at GlaxoSmithKline R&D

Tony Wood to assume full accountability for GSK R&D in August 2022 Hal Barron to transition in August 2022 from CSO to a GSK Non-Executive Director with additional responsibilities to support R&D (PRESS RELEASE) LONDON, 19-Jan-2022 — /EuropaWire/ — GlaxoSmithKline … Read the full press release

GlaxoSmithKline to present comprehensive portfolio of respiratory research and scientific innovation at the American Thoracic Society (ATS) conference

Brentford, United Kingdom, 17-May-2018 — /EuropaWire/ — GlaxoSmithKline plc (GSK) will present extensive data from across its respiratory portfolio, pipeline and early phase research programmes at the American Thoracic Society (ATS) conference in San Diego, USA, 19-23 May 2018. Data presented … Read the full press release

Japanese Ministry of Health, Labour and Welfare (MHLW) granted approval for GSK’s Nucala® as a treatment for bronchial asthma

LONDON, 29-Mar-2016 — /EuropaWire/ — GlaxoSmithKline plc (LSE/NYSE:GSK) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval for Nucala® (mepolizumab) as a treatment for bronchial asthma in patients with refractory asthma whose symptoms are inadequately … Read the full press release